RadNet Takes Global Leadership in Radiology AI
RadNet, Inc. has acquired Gleamer SAS, a Paris-based radiology artificial intelligence company, in an all-cash transaction valued at up to $269.92 million. The acquisition integrates Gleamer into DeepHealth, RadNet’s wholly owned subsidiary, creating what the company calls the largest clinical radiology AI provider worldwide — with over 2,700 customer contracts across 50+ countries and a combined portfolio of 26 FDA-cleared and 22 CE-marked devices.
Gleamer, founded in France in 2017, employs over 130 professionals and serves 700+ customer contracts across 44 countries. Its portfolio includes four FDA-cleared and six CE-marked AI solutions covering 25 clinical indications in musculoskeletal, breast, lung and neurologic applications. The company achieved a compound annual growth rate exceeding 90% from 2022 to 2025.
RadNet’s acquisition strategy goes beyond Gleamer alone. The company has committed over $344 million to acquisitions in 2026, signaling an aggressive consolidation play in the radiology AI market.
Strategic Rationale Behind the Deal
RadNet CEO Dr. Howard Berger explained that the decision is directly tied to radiology’s staffing crisis. As imaging volumes rise amid an accelerating global radiologist shortage, reengineering high-volume workflows has become essential — particularly in modalities like X-ray, ultrasound and mammography, where Gleamer holds established expertise.
“For radiologists and providers, the key lies in advancing automated exam prioritization and draft reporting,” Berger said during the company’s quarterly earnings call. “The acquisition of Gleamer uniquely positions DeepHealth to expand its impact across routine imaging and high-impact acute diagnostic care.”
Gleamer co-founder and CEO Christian Allouche stated: “By combining our AI capabilities, product portfolio and strong commercial team with that of DeepHealth, we are poised to shape the future of intelligent imaging at scale.”
Combined Portfolio and Technical Capabilities
Integrating Gleamer’s portfolio with DeepHealth’s clinical AI suites for breast, chest, neuro, prostate and thyroid creates what RadNet describes as a portfolio “unrivaled by any other radiology AI company.” The combined suite supports screening, detection, interpretation and follow-up across many prevalent cancer types, plus neurodegenerative and musculoskeletal conditions.
With Gleamer’s products — especially its market-leading X-ray solutions, which account for nearly 25% of RadNet’s imaging volume — the company plans to implement an end-to-end AI-enabled workflow. This begins with triaging critical findings to accelerate interpretation of the most urgent cases, aligning with trends in agentic AI for radiological follow-up.
Gleamer’s automated reporting capabilities, already deployed across Europe, combined with DeepHealth’s AI and informatics portfolio, bring clinical, generative and agentic AI together with imaging informatics into a unified offering.
Scale and Financial Projections
Combined, DeepHealth and Gleamer employ 550+ professionals across four continents, with 75+ clinical indications covering MR, CT, X-ray, mammography and ultrasound. The companies anticipate achieving annual recurring revenue (ARR) approaching or exceeding $140 million by end of 2026.
The acquisition also brings Gleamer’s commercial team of 40+ members, primarily in Europe, along with 80 additional R&D employees. This marks the latest in RadNet’s technology acquisition streak, following iCAD ($103M), See-Mode Technologies ($29M), Cimark UK ($33M), Kheiron Medical Technologies, and Alpha RT — with the company now operating over 430 freestanding imaging centers.
Market Implications
RadNet’s consolidation signals a structural shift in the radiology AI market. While smaller AI companies struggle to scale individually, DeepHealth’s platform strategy — combining clinical, operational and generative AI into an integrated ecosystem — may set a new industry standard. The deal accelerates the introduction of draft reporting capabilities, allowing radiologists to increase reading volumes with greater accuracy, a development closely watched alongside innovations in AI-powered breast cancer screening.
Sources: ITN Online | Radiology Business | Health Imaging